Abstract:Multidrug resistance proteins (MRP2, ABCC2) may play a role in drug resistance in epilepsy by limiting gastrointestinal absorption and brain access of antiepileptic drugs (AEDs). We sought to investigate the effects of ABCC2 polymorphisms on plasma carbamazepine (CBZ) concentrations and pharmacoresistance in Chinese patients with epilepsy. ABCC2 rs717620, rs2273697, rs3740066 polymorphisms were genotyped by polymerase chain reaction amplification followed by restriction fragment length polymorphism analysis or direct automated DNA sequencing in 80 patients treated with CBZ monotherapy. There were no differences in CBZ maintenance doses or adjusted plasma CBZ concentrations among the ABCC2 rs717620, rs2273697 and rs3740066 genotypic groups. No associations between all the studied genotypes and haplotypes involving the three SNPs of ABCC2 and CBZ resistance were observed in this patient cohort. These results suggest that ABCC2 polymorphisms may not contribute to interindividual variabilities in CBZ daily maintenance doses, plasma concentrations, and treatment efficacy. Neurology Asia 2015; 20(3) : 221 – 227 Address correspondence to: Yingjie Guo, School of Life Sciences, Jilin University, Changchun, 130021, China. Tel: +86-431-85155316; Fax:+86-431-85155316; E-mail: guoyingjie@jlu.edu.cn INTRODUCTION Carbamazepine (CBZ) is one of the most frequently prescribed anticonvulsant drugs for the treatment of epileptic seizures. Wide variabilities of CBZ daily maintenance doses, plasma concentrations, and treatment efficacy have been observed among patients treated with this agent. There is evidence that drug efflux transporters may play a role in drug-resistant epilepsy by limiting gastrointestinal absorption and brain access of antiepileptic drugs (AEDs). Therefore, genetic variants of drug transporter genes associated with functional variations in efflux activity may influence CBZ plasma concentration and treatment efficacy. Drug transporters are members of the membrane transport protein families belonging to either ATP-binding cassette (ABC) or solutelinked carrier super family of proteins. Among them, P-glycoprotein (P-gp), encoded by ABCB1 (or MDR1), is an extensively studied drug efflux transporter in epilepsy. Although it remains equivocal whether CBZ is a substrate of P-gp, numerous studies have explored the role of ABCB1 polymorphisms on the drug response in different ethnicities. Recently, multidrug resistance proteins (MRP2, ABCC2), have been shown to mediate CBZ transport. Increased expressions of ABCC2 have been observed in brain tissues of patients with refractory epilepsy. It was hypothesized that genetic variations in the ABCC2 gene would probably affect individual drug responses to CBZ. ABCC2 rs717620, rs2273697 and rs3740066 are the major functional genetic variants, which have been characterized for their influence on the respective mRNA, protein expression, or oral clearance of drug substrates. Choi et al. showed that the combined variation of rs1885301and rs717620 decreased ABCC2 promoter activity by 39%. Laechelt et al. demonstrated both a decrease and an increase in ABCC2 expression or activity with different haplotypic combinations of rs717620, rs2273697 and rs3740066, which is supported by functional data showing these ABCC2 polymorphims affected the clearance of Neurology Asia September 2015 222 mycophenolic acid, methotrexate or irinotecan. Recently, Puranik et al. reported that the rs2273697 variant was associated with higher CBZ clearance, and adverse neurological drug reactions to CBZ, but there are some conflicting results in other studies. These conflicting results reinforce the need to check the functional significance of ABCC2 polymorphisms in different ethnic groups. The present study was performed to evaluate associations of the rs717620, rs2273697 and rs3740066 genotypes of ABCC2 and their haplotypic combinations with CBZ plasma levels and treatment efficacy in Chinese patients with epilepsy.

A Genome-Wide Association Study of Sodium Levels and Drug Metabolism in an Epilepsy Cohort Treated with Carbamazepine and Oxcarbazepine.

Carbamazepine‐ and Oxcarbazepine‐induced Hyponatremia in People with Epilepsy

Comprehensive Analysis of the Association of SCN1A Gene Polymorphisms with the Retention Rate of Carbamazepine Following Monotherapy for New‐onset Focal Seizures in the Chinese Han Population

Effects of SCN1A and GABA Receptor Genetic Polymorphisms on Carbamazepine Tolerability and Efficacy in Chinese Patients with Partial Seizures: 2-Year Longitudinal Clinical Follow-Up.

Differences in associations of antiepileptic drugs and hospitalization due to hyponatremia: A population-based case-control study

Genetic Predictors of the Maximum Doses Patients Receive During Clinical Use of the Anti-Epileptic Drugs Carbamazepine and Phenytoin

Association between two functional SNPs of SCN1A gene and efficacy of carbamazepine monotherapy for focal seizures in Chinese Han epileptic patients.

ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients

Effects of Major Transporter and Metabolizing Enzyme Gene Polymorphisms on Carbamazepine Metabolism in Chinese Patients with Epilepsy

Effects of ABCB1, ABCC2, UGT2B7 and HNF4α Genetic Polymorphisms on Oxcarbazepine Concentrations and Therapeutic Efficacy in Patients with Epilepsy.

Association Study of the Efficacy Genetic with the Blood Concentration of Carbamazepine

Lack of association between ABCC 2 polymorphisms and plasma carbamazepine concentrations or pharmacoresistance in Chinese patients with epilepsy

Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI

Genetic Polymorphisms in Enzymes Involved in One-Carbon Metabolism and Anti-epileptic Drug Monotherapy on Homocysteine Metabolism in Patients with Epilepsy

Association Study of Cyp3a5 Genetic Polymorphism with Serum Concentrations of Carbamazepine in Chinese Epilepsy Patients

CYP2C19 genotype and sodium channel blockers in lacosamide-treated children with epilepsy: two major determinants of trough lacosamide concentration or clinical response

Genome‐wide Association Study: Exploring the Genetic Basis for Responsiveness to Ketogenic Dietary Therapies for Drug‐resistant Epilepsy

Pharmacogenetic Variants and Plasma Concentrations of Antiseizure Drugs: A Systematic Review and Meta-Analysis

The association of ABCB1 gene polymorphism with clinical response to carbamazepine monotherapy in patients with epilepsy

Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy

Impact of ABCB1 genetic polymorphism on carbamazepine dose requirement among Southern Indian persons with epilepsy